Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium.

MLA

Robbins, Hilary A., et al. “Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 40, no. 31, Nov. 2022, pp. 3613–22. EBSCOhost, https://doi.org/10.1200/JCO.21.01785.

APA

Robbins, H. A., Ferreiro-Iglesias, A., Waterboer, T., Brenner, N., Nygard, M., Bender, N., Schroeder, L., Hildesheim, A., Pawlita, M., D’Souza, G., Visvanathan, K., Langseth, H., Schlecht, N. F., Tinker, L. F., Agalliu, I., Wassertheil-Smoller, S., Ness-Jensen, E., Hveem, K., Grioni, S., … Brennan, P. (2022). Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 40(31), 3613–3622. https://doi.org/10.1200/JCO.21.01785

Chicago

Robbins, Hilary A, Aida Ferreiro-Iglesias, Tim Waterboer, Nicole Brenner, Mari Nygard, Noemi Bender, Lea Schroeder, et al. 2022. “Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 40 (31): 3613–22. doi:10.1200/JCO.21.01785.